STOCK TITAN
  1. Home
  2. Sec-filings
  3. LEXX
  4. [8-K] Lexaria Bioscience Corp. Reports Material Event

Lexaria Bioscience to raise $5.9M via warrant deal

Lexaria Bioscience expects about $5.9 million in gross proceeds from warrant exercises and will issue new Series A and B warrants in a concurrent private placement.

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Lexaria Bioscience Corp. (LEXX) entered into definitive agreements for the immediate exercise of outstanding warrants to purchase 453,969 shares of common stock at a reduced exercise price of $12.92 per share, with closing expected on or about September 9, 2026, subject to customary conditions.

In return for cash exercise of these registered warrants, Lexaria will issue in a private placement new unregistered Series A and Series B warrants for up to 453,969 shares each, both exercisable immediately at $12.67 per share. Series A warrants will expire five years after the effective date of a resale registration statement, while Series B warrants will expire eighteen months after that date.

The transaction is expected to generate approximately $5.9 million in gross proceeds before fees, which, together with a recently received $2.6 million tax rebate from the Australian Tax Office, is expected to be used for working capital and to support operations and research and development programs in 2027. Lexaria highlights its DehydraTECH drug delivery platform and a portfolio of 66 granted patents worldwide.

Positive

  • None.

Negative

  • None.

Filing Explained

For scale, at May 31, 2026, Lexaria reported $3,500,000 in cash and $142,103 in short-term investments; together, that liquidity equals 204.9 days of the last reported quarterly operating cash use at that rate.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate ($3,500,000 + $142,103) / ($1,635,020 / 92) = 204.9 days
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Shares subject to immediate warrant exercise 453,969 shares Outstanding warrants to be exercised at reduced price
Reduced exercise price $12.92 per share Price for immediate exercise of existing warrants
New warrant exercise price $12.67 per share Exercise price for Series A and Series B New Warrants
Expected gross proceeds $5.9 million Gross cash proceeds expected from warrant exercises before fees
Australian tax rebate $2.6 million Tax rebate recently received from the Australian Tax Office
Series A warrant term 5 years Expires five years from effective date of resale registration
Series B warrant term 18 months Expires eighteen months from effective date of resale registration
Granted patents 66 patents Size of Lexaria’s granted patent portfolio worldwide
warrants financial
"exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
gross proceeds financial
"The gross proceeds to the Company from the exercise of the warrants"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.
registration statement regulatory
"registered pursuant to effective registration statements on Form S-1 and Form S-3"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.
private placement financial
"The New Warrants described above are being offered in a private placement"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Resale Registration Statement regulatory
"will expire five years from the effective date of the Resale Registration Statement"
A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.
forward-looking statements regulatory
"This press release includes forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

What financing transaction did LEXX announce in this 8-K?
Lexaria announced agreements for the immediate exercise of certain outstanding warrants for 453,969 shares of common stock at a reduced exercise price of $12.92 per share, with closing expected on or about September 9, 2026, subject to satisfaction of customary closing conditions.

How much cash does Lexaria (LEXX) expect to receive from the warrant exercise?
Lexaria expects to receive approximately $5.9 million in gross proceeds from the warrant exercises, before deducting placement agent fees and other offering expenses. The company plans to use the net proceeds for working capital and general corporate purposes.

What are the key terms of Lexaria’s new Series A and Series B warrants?
Lexaria will issue new Series A and Series B warrants to purchase up to 453,969 shares each at an exercise price of $12.67 per share. Both are exercisable immediately; Series A expires five years and Series B eighteen months from the effective date of a resale registration statement.

Are the new Lexaria (LEXX) warrants and their underlying shares registered?
The new Series A and Series B warrants and the shares issuable upon their exercise are being offered in a private placement and are not registered under the 1933 Act. Lexaria has agreed to file a resale registration statement with the SEC as soon as practicable.

How does the recent Australian tax rebate factor into Lexaria’s plans?
Lexaria’s CEO noted that the $2.6 million tax rebate recently received from the Australian Tax Office, together with the potential $5.9 million in gross proceeds from warrant exercises, may be used to fund the company’s operations and research and development programs in 2027.

What technology and IP position does Lexaria (LEXX) highlight in this announcement?
Lexaria highlights its patented DehydraTECH drug delivery platform, designed to improve oral drug bio-absorption and blood-brain barrier delivery, and notes it holds 66 granted patents with additional patents pending worldwide.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

  EXHIBIT 99.1

 

 

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

 

Tuesday, 08 September 2026 08:00 AM

 

Topic: Financing

 

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price of $20.55 per share and on December 16, 2025, having an original exercise price of $17.85 per share, at a reduced exercise price of $12.92 per share. The closing of the warrant exercise transaction is expected to occur on or about September 9, 2026, subject to satisfaction of customary closing conditions.

 

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

 

The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-277863), Form S-3 (File No. 333-283484), Form S-1 (File No. 333-290862), and Form S-1 (File No. 333-292469).

 

In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered Series A warrants to purchase up to an aggregate of 453,969 shares of common stock (the "Series A Warrants") and short-term Series B warrants (the "Series B Warrants," and together with the Series A Warrants, the "New Warrants") to purchase up to an aggregate of 453,969 shares of common stock. The Series A Warrants will have an exercise price of $12.67 per share, will be exercisable immediately upon issuance and will expire five years from the effective date of the Resale Registration Statement (defined below). The Series B Warrants will have an exercise price of $12.67 per share, will be exercisable immediately upon issuance and will expire eighteen months from the effective date of the Resale Registration Statement.

 

The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $5.9 million, prior to deducting placement agent fees and other offering expenses. The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes.

 

"We are extremely pleased for the potential $5.9 million in gross cash proceeds from the exercise of warrants" said Rich Christopher, CEO of Lexaria. "The potential proceeds from this transaction, in combination with the $2.6 million tax rebate that we recently received from the Australian Tax Office, may be utilized to fund our operations and research and development programs in 2027."

 

 
1

 

 

The New Warrants described above are being offered in a private placement and, along with the shares of common stock issuable upon exercise of the New Warrants, have not been registered under the Securities Act of 1933, as amended (the "1933 Act"), or applicable state securities laws. Accordingly, the New Warrants and shares of common stock issuable upon the exercise of the New Warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the 1933 Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission ("SEC") as soon as practicable covering the resale of the shares of common stock issuable upon exercise of the New Warrants (the "Resale Registration Statement").

 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

 

About Lexaria Bioscience Corp. & DehydraTECH

 

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

 

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

 

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the satisfaction of customary closing conditions, the intended use of proceeds from the offering, the anticipated closing of the offering, the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

 

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations

ir@lexariabioscience.com

Phone: 250-765-6424, ext. 202

 

SOURCE: Lexaria Bioscience Corp.

 

 
2

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

9 documents

Press Releases

Agreements & Contracts

Other Documents

Keep reading

More on LEXX

Trending in the feed

Open the live feed